2. Signaling Pathways
  3. Epigenetics
  4. Glycosyltransferase
  5. Glycosyltransferase Inhibitor

Glycosyltransferase Inhibitor

Glycosyltransferase Inhibitors (14):

Cat. No. Product Name Effect Purity
  • HY-129389
    Benzyl-α-GalNAc
    		Inhibitor 99.93%
    Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-Fluorouracil (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation.
  • HY-W096600
    2F-Peracetyl-Fucose
    		Inhibitor 99.54%
    2F-Peracetyl-Fucose (1,3,4-Tri-O-acetyl-2-deoxy-2-fluoro-L-fucopyranos) acts as a potent fucosyltransferase (FUT) inhibitor.
  • HY-107366
    SGN-2FF
    		Inhibitor 98.0%
    SGN-2FF is a potent and orally active inhibitor of fucosylation, directly inhibits fucosyltransferase activity. SGN-2FF possesses antitumor activity.
  • HY-139056
    SU0268
    		Inhibitor 99.96%
    SU0268 is a potent and specific inhibitor of 8-Oxoguanine DNA glycosylase 1 (OGG1). SU0268 regulates inflammatory responses during Pseudomonas aeruginosa infection.
  • HY-125961
    T3Inh-1
    		Inhibitor 99.93%
    T3Inh-1 is a potent and selective inhibitor of ppGalNAc-T3 (IC50=7 μM). T3Inh-1 reduces FGF23 hormone levels in both tissue cells and mice, without causing any toxic side effects. T3Inh-1 also prevents breast cancer cells. The enzyme ppGalNAc-T3 is implicated in at least two medically important pathways: cancer metastasis and stabilization of FGF23 (regulates phosphate levels in the bloodstream).
  • HY-115625
    AG-205
    		Inhibitor 99%
    AG-205 is a progesterone receptor membrane component 1 (PGRMC1) antagonist and CGT inhibitor, with an IC50 of 50 μM against rat CGT. AG-205 exhibits antimitotic, antimigratory and anti-invasive activities. AG-205 increases the expression of genes encoding cholesterol biosynthesis pathway or steroidogenic enzymes. AG-205 promotes the regulation of cell cycle by apoptosis and reduces the migratory and invasive capacities of ovarian and breast cancer cells. AG-205 can be used in research related to renal cancer and breast cancer.
  • HY-131062
    yGsy2p-IN-1
    		Inhibitor 98.57%
    yGsy2p-IN-1 is a potent inhibitor for yeast glycogen synthase 2 (yGsy2p). yGsy2p-IN-1 is a competitive human glycogen synthase 1 (hGYS1) inhibitor with an IC50 of 2.75 μM and a Ki of 1.31 μM for wild-type hGYS1. yGsy2p-IN-H23 a pyrazole inhibitor, is used for glycogen storage diseases (GSDs).
  • HY-163121
    PST3.1a
    		Inhibitor
    PST3.1a is an orally active and brain-penetrant N-acetylglucosamine glycosyltransferase (MGAT5) inhibitor with a human IC50 of 2 µM. PST3.1a inhibits TGFβR and FAK signaling pathway activity. PST3.1a alters β1,6-GlcNAc N-glycans and microtubule/microfilament integrity, increases OLIG2 expression, and inhibits proliferation, migration, invasiveness, and clonogenic capacities of glioblastoma initiating cells. PST3.1a reduces invasive and proliferative capacity of glioblastoma initiating cells in orthotopic graft models, increases overall survival of orthotopic graft model mice. PST3.1a blunts MGAT5 overexpression, decreases renal fibrosis via collagen 1, collagen 4, and galectin 3 downregulation in a rat chronic kidney disease model. PST3.1a can be used for the research of glioblastoma multiforme and chronic kidney disease.
  • HY-170663
    β-1,4-GALT1-IN-1
    		Inhibitor
    β-1,4-GALT1-IN-1 (Compound 6) is a β-1,4-GALT1 inhibitor, with an IC50 value of 6.2 μM. β-1,4-GALT1-IN-1 can be used in many pathology investigations such as cancer, autoimmune diseases and viral infections.
  • HY-169084
    ST-IN-1
    		Inhibitor
    ST-IN-1 (compound (R)-1) is a selective ST inhibitor (Ki=70 nM, rat a-2,6-ST; Ki=19 nM, hST6GAL1) with antitumor activity. ST-IN-1 inhibits tumor growth and metastasis by delipidating the surface of tumor cells.
  • HY-156155
    GYS1-IN-1
    		Inhibitor
    GYS1-IN-1 (compound 783) is a glycogen synthase 1(GYS1) inhibitor. GYS1-IN-1 can be used for the study of GYS1 -mediated disease, such as Gaucher and Fabry diseases.
  • HY-147960
    Glycosyltransferase-IN-1
    		Inhibitor
    Glycosyltransferase-IN-1 (compound 5m) is a potent glycosyltransferase inhibitor, with an IC50 of 82.8 μM. Glycosyltransferase-IN-1 shows antibacterial activity, with MIC values of 6 μg/mL for MSSA, MRSA, B. subtilis and 12 μg/mL for E. coli.
  • HY-175697
    Glycosyltransferase-IN-2
    		Inhibitor
    Glycosyltransferase-IN-2 (Compound 20) is a Glycosyltransferase inhibitor. Glycosyltransferase-IN-2 has a broad-spectrum anticoronavirus activity with IC50s of 11.3, 5.5 and ~16.2 μM for MHV, HCoV-NL63 and SARS-CoV-2, respectively. Glycosyltransferase-IN-2 interferes with the coronavirus infectivity, alters viral protein glycosylation with inhibition of interaction with the ACE2 receptor or SC-VLP secretion, and inhibits RNA replication. Glycosyltransferase-IN-2 can be used for coronavirus infections research.
  • HY-107366R
    SGN-2FF (Standard)
    		Inhibitor
    SGN-2FF (Standard) is the analytical standard of SGN-2FF (HY-107366). This product is intended for research and analytical applications. SGN-2FF is a potent and orally active inhibitor of fucosylation, directly inhibits fucosyltransferase activity. SGN-2FF possesses antitumor activity.